John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive


Comment faire le bilan et surveiller une TIPMP ? Volume 24, numéro 1, Janvier 2017

  • [1] Oh H.C., Kim M.H., Hwang C.Y. Cystic Lesions of the Pancreas : Challenging Issues in Clinical Practice. Am J Gastroenterol. 2008;103:229-239.
  • [2] de Jong K., Nio C.Y., Hermans J.J. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol. 2010;8:806-811.
  • [3] Lee K.S., Sekhar A., Rofsky N.M. Prevalence of Incidental Pancreatic Cysts in the Adult Population on MR Imaging. Am J Gastroenterol. 2010;105:2079-2084.
  • [4] Fernández-del Castillo C., Adsay N.V. Intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology. 2010;139:708-713.
  • [5] Farrell JJ, Fernández-del Castillo C. Pancreatic cystic neoplasms : management and unanswered questions. Gastroenterology 2013 ; 144 : 1303-15.
  • [6] Fong Z.V., Ferrone C.R., Lillemoe K.D. Intraductal Papillary Mucinous Neoplasm of the Pancreas : Current State of the Art and Ongoing Controversies. Ann Surg. 2016;263:908-917.
  • [7] Lévy P., Jouannaud V., O’Toole D. Natural history of intraductal papillary mucinous tumors of the pancreas : actuarial risk of malignancy. Clin Gastroenterol Hepatol. 2006;4:460-468.
  • [8] Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012 ; 12 : 183-97.
  • [9] Singhi A.D., Nikiforova M.N., Fasanella K.E. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res. 2014;20:4381-4389.
  • [10] Berger A.W., Schwerdel D., Costa I.G. Detection of hot-spot mutations in circulating cell-free DNA from patients with intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology. 2016;151:267-270.
  • [11] Crippa S, Bassi C, Salvia R, et al. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management : a mid-term follow-up analysis. Gut. 2016 Jan 7.
  • [12] Mukewar S., de Pretis N., Aryal-Khanal A. Fukuoka criteria accurately predict risk for adverse outcomes during follow-up of pancreatic cysts presumed to be intraductal papillary mucinous neoplasms. Gut. 2016.
  • [13] Vege S.S., Ziring B., Jain R. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819-822.
  • [14] Lafemina J., Katabi N., Klimstra D. Malignant progression in IPMN : a cohort analysis of patients initially selected for resection or observation. Ann Surg Oncol. 2013;20:440-447.
  • [15] Kim K.W., Park S.H., Pyo J. Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas : A meta-analysis. Ann Surg. 2014;259:72-81.
  • [16] Robles E.P., Maire F., Cros J. Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas. United European Gastroenterol J. 2016;4:580-586.
  • [17] Del Chiaro M, Verbeke C, Salvia R, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis 2013 ; 45 : 703-11.
  • [18] Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013 ; 62 : 339-47.